Furthermore, a Kaplan–Meier survival analysis performed with the GEPIA database demonstrated that low SESN2 expression is associated with a reduced overall survival rate in prostate cancer patients (Figure 1(c)). This evidence concerns the gene SESN2 and prostate carcinoma.